|
|
 |
|
Viewing report
|
|
|
|
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
Frost & Sullivan, May 2003
New Non-stimulants Attract Broader User Base
The non-addictive properties of new non-stimulants have given an impetus to the market for attention deficit hyperactivity disorder (ADHD) medication. Strattera, the first Food and Drug Administration-approved non-stimulant therapy for ADHD, has an expansive user base because of its unique efficacy in the treatment of adults, adolescents, and children. Substance use disorder, a serious concern among adolescent and adult stimulant users who are prone to alcohol and drug abuse, is not a cause of major worry in the case of non-stimulant drugs such as Strattera. Since Strattera does not activate pleasure sensors in the brain, it does not become addictive even in high doses.
This Frost & Sullivan research examines the U.S. Attention Deficit Hyperactivity Disorder Markets. It offers revenue forecasts by market and end-user segments, covers key drivers and restraints, as well as provides strategic recommendations to overcome market challenges.
Simultaneous Treatment of ADHD and Comorbidities Creates Opportunities for Combination Therapies
Occurrence of comorbidities such as learning disabilities, conduct as well as anxiety disorders, and depression generates numerous prospects for combination therapies, collaboration, co-branding, and bundling initiatives in the ADHD medication market. The requirement for concurrent treatment of ADHD and its comorbidities provide opportunities to design products that broaden treatment options. The demand for combination medication is especially high for children since parents are particularly concerned about the harmful effects of multiple medications on their growth and development, notes the analyst.
Combination therapies, by providing patients with comprehensive solutions to their disorders, reduce medication burden, contraindications, as well as enhance convenience. The need to combine formulations for this type of therapy establishes possibilities for strategic partnerships. Collaborations help reduce marketing expenses by enabling pharmaceutical companies to co-promote products. Generic participants are likely to be presented with new options since patent and market exclusivity rights are expected to expire soon.
Underserved Patient Base to Provide a Gateway for Market Expansion Initiatives
With 4 percent of the adult population believed to be impacted by ADHD and a treatment penetration rate of under 10 percent, there is significant opportunity for market expansion initiatives gained through supplemental applications, observes the analyst. A majority of ADHD patients, especially the inattentive and combined subtypes, carries ADHD symptoms into adulthood. Several drugs meant for this user segment are under trial. Greater compliance is expected from the adult market since it is less sensitive than the child sector. This section of patients is growing rapidly and is anticipated to be highly profitable in future.
Targeted strategies are likely to succeed in a market where some population groups such as non-Caucasians report low treatment penetration rates. Only about half the child and adolescent market has been tapped and even within that, the patient needs of the female sector have been relatively unmet. Advances in diagnostic technology, greater awareness about the disorder, and introduction of a new objective diagnostic technique are forecast to double the number of people seeking therapy in the long term.
Additional InformationThe following technologies are included in this report
Attention Deficit Hyperactivity Disorder (ADHD): ADHD is a neurobehavioral disorder and is the most commonly diagnosed childhood behavioral disorder. ADHD is classified under three subtypes: predominantly inattentive, predominantly hyperactive and combined types. Furthermore, a number of other conditions occur with ADHD known as comorbidities. Examples of comorbidities include depression, anxiety disorder, bipolar disorder, conduct disorder and others. The U.S. ADHD markets include the stimulant therapies and non-stimulant therapies market segments.
|
|
|
|
